<PubmedArticle xmlns:ns0="http://www.w3.org/1998/Math/MathML"><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39433797</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>21</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>25</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>21</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Disease progression associated cytokines in COVID-19 patients with deteriorating and recovering health conditions.</ArticleTitle><Pagination><StartPage>24712</StartPage><MedlinePgn>24712</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">24712</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-024-75924-x</ELocationID><Abstract><AbstractText>Understanding the immune response to COVID-19 is challenging due to its high variability among individuals. To identify differentially expressed cytokines between the deteriorating and recovering phases, we analyzed the Electronic Health Records (EHR) and cytokine profile data in a COVID-19 cohort of 444 infected patients and 145 non-infected healthy individuals. We categorized each patient's progression into Deterioration Phase (DP) and Recovery Phase (RP) using longitudinal neutrophil, lymphocyte and lactate dehydrogenase levels. A random forest model was built using healthy and severe patients to compute the contribution of each cytokine toward disease progression using Shapley Additive Explanations (SHAP). SHAP values were used for supervised clustering to identify DP and RP-related samples and their associated cytokines. The identified clusters effectively discriminated DP and RP samples, suggesting that the cytokine profiles differed between deteriorating and recovering health conditions. Especially, CXCL10, GDF15, PTX3, and TNFSF10 were differentially expressed between the DP and RP samples, which are involved in the JAK-STAT, NF- <ns0:math><ns0:mi>κ</ns0:mi></ns0:math> B, and MAPK signaling pathways contributing to the inflammatory response. Collectively, we characterized the immune response in terms of disease progression of COVID-19 with deteriorating and recovering health conditions.</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Han</LastName><ForeName>Eonyong</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>School of Computer Science and Engineering, Kyungpook National University, Daegu, 41566, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Youn</LastName><ForeName>Sohyun</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>School of Computer Science and Engineering, Kyungpook National University, Daegu, 41566, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kwon</LastName><ForeName>Ki Tae</ForeName><Initials>KT</Initials><AffiliationInfo><Affiliation>Kyungpook National University Chilgok Hospital, 807 Hoguk-ro, Buk-gu, Daegu, 41404, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Sang Cheol</ForeName><Initials>SC</Initials><AffiliationInfo><Affiliation>Division of Healthcare and Artificial Intelligence, Department of Precision Medicine, Korea National Institute of Health, Korea Disease Control and Prevention Agency, Osong, Cheongju-si, 28159, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jo</LastName><ForeName>Hye-Yeong</ForeName><Initials>HY</Initials><AffiliationInfo><Affiliation>Division of Healthcare and Artificial Intelligence, Department of Precision Medicine, Korea National Institute of Health, Korea Disease Control and Prevention Agency, Osong, Cheongju-si, 28159, Republic of Korea. jhy1227@korea.kr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jung</LastName><ForeName>Inuk</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>School of Computer Science and Engineering, Kyungpook National University, Daegu, 41566, Republic of Korea. inukjung@knu.ac.kr.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>HG22C0014</GrantID><Agency>Infectious Disease Medical Safety, funded by the Ministry of Health and Welfare, South Korea</Agency><Country /></Grant><Grant><GrantID>HG22C0014</GrantID><Agency>Infectious Disease Medical Safety, funded by the Ministry of Health and Welfare, South Korea</Agency><Country /></Grant><Grant><GrantID>HG22C0014</GrantID><Agency>Infectious Disease Medical Safety, funded by the Ministry of Health and Welfare, South Korea</Agency><Country /></Grant><Grant><GrantID>HG22C0014</GrantID><Agency>Infectious Disease Medical Safety, funded by the Ministry of Health and Welfare, South Korea</Agency><Country /></Grant><Grant><GrantID>2024-ER-0801-00</GrantID><Agency>National Institute of Health research projects</Agency><Country /></Grant><Grant><GrantID>2024-ER-0801-00</GrantID><Agency>National Institute of Health research projects</Agency><Country /></Grant><Grant><GrantID>2024-ER-0801-00</GrantID><Agency>National Institute of Health research projects</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="Y">Cytokines</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="Y">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Cytokine</Keyword><Keyword MajorTopicYN="N">Disease progression</Keyword><Keyword MajorTopicYN="N">Longitudinal</Keyword><Keyword MajorTopicYN="N">Severity</Keyword></KeywordList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>4</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>22</Day><Hour>0</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>22</Day><Hour>0</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>21</Day><Hour>23</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>21</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39433797</ArticleId><ArticleId IdType="pmc">PMC11494080</ArticleId><ArticleId IdType="doi">10.1038/s41598-024-75924-x</ArticleId><ArticleId IdType="pii">10.1038/s41598-024-75924-x</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Davies, N. G. et al. Age-dependent effects in the transmission and control of COVID-19 epidemics. Nat. Med. 26, 1205–1211 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32546824</ArticleId></ArticleIdList></Reference><Reference><Citation>Gebhard, C., Regitz-Zagrosek, V., Neuhauser, H. K., Morgan, R. &amp; Klein, S. L. Impact of sex and gender on COVID-19 outcomes in Europe. Biol. Sex Differ. 11, 1–13 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7247289</ArticleId><ArticleId IdType="pubmed">32450906</ArticleId></ArticleIdList></Reference><Reference><Citation>Russell, C. D., Lone, N. I. &amp; Baillie, J. K. Comorbidities, multimorbidity and COVID-19. Nat. Med. 29, 334–343 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">36797482</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubio-Rivas, M. et al. Who ordinal scale and inflammation risk categories in COVID-19. Comparative study of the severity scales. J. General Intern. Med. 37, 1980–1987 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8992782</ArticleId><ArticleId IdType="pubmed">35396659</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwab, P. et al. Real-time prediction of COVID-19 related mortality using electronic health records. Nat. Commun. 12, 1058 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7886884</ArticleId><ArticleId IdType="pubmed">33594046</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnett, W. R. et al. Initial mews score to predict ICU admission or transfer of hospitalized patients with COVID-19: A retrospective study. J. Infect. 82, 282–327 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7462753</ArticleId><ArticleId IdType="pubmed">32888979</ArticleId></ArticleIdList></Reference><Reference><Citation>Mueller, Y. M. et al. Stratification of hospitalized COVID-19 patients into clinical severity progression groups by immuno-phenotyping and machine learning. Nat. Commun. 13, 915 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8854670</ArticleId><ArticleId IdType="pubmed">35177626</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang, L. et al. The signal pathways and treatment of cytokine storm in COVID-19. Signal Transduct. Target. Ther. 6, 255 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8261820</ArticleId><ArticleId IdType="pubmed">34234112</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu, A., Hammond, R., Donnelly, P. D., Kaski, J. C. &amp; Coates, A. R. Effective prognostic and clinical risk stratification in COVID-19 using multimodality biomarkers. J. Intern. Med. 294, 21–46 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37106509</ArticleId></ArticleIdList></Reference><Reference><Citation>Tiwari, S. et al. Applications of machine learning approaches to combat covid-19: A survey. Lessons COVID-19 263–287 (2022).</Citation></Reference><Reference><Citation>Caron, R. M. &amp; Adegboye, A. R. A. Covid-19: A syndemic requiring an integrated approach for marginalized populations. Front. Public Health 9, 675280 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8144466</ArticleId><ArticleId IdType="pubmed">34046392</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomes, R. et al. A comprehensive review of machine learning used to combat COVID-19. Diagnostics 12, 1853 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9406981</ArticleId><ArticleId IdType="pubmed">36010204</ArticleId></ArticleIdList></Reference><Reference><Citation>Painuli, D., Mishra, D., Bhardwaj, S. &amp; Aggarwal, M. Forecast and prediction of COVID-19 using machine learning. In Data Science for COVID-19, 381–397 (Elsevier, 2021).</Citation></Reference><Reference><Citation>Meraihi, Y., Gabis, A. B., Mirjalili, S., Ramdane-Cherif, A. &amp; Alsaadi, F. E. Machine learning-based research for COVID-19 detection, diagnosis, and prediction: A survey. SN Comput. Sci. 3, 286 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9096341</ArticleId><ArticleId IdType="pubmed">35578678</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan, L. et al. An interpretable mortality prediction model for COVID-19 patients. Nat. Mach. Intell. 2, 283–288 (2020).</Citation></Reference><Reference><Citation>Ballouz, T. et al. Recovery and symptom trajectories up to two years after SARS-CoV-2 infection: Population based, longitudinal cohort study. BMJ 381, e074425 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10230608</ArticleId><ArticleId IdType="pubmed">37257891</ArticleId></ArticleIdList></Reference><Reference><Citation>Kassie, M. Z., Gobena, M. G., Alemu, Y. M. &amp; Tegegne, A. S. Time to recovery and its determinant factors among patients with COVID-19 in Assosa COVID-19 treatment center, Western Ethiopia. Pneumonia 15, 17 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10625712</ArticleId><ArticleId IdType="pubmed">37925445</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu, J. et al. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. EBioMedicine 55, 102763 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7165294</ArticleId><ArticleId IdType="pubmed">32361250</ArticleId></ArticleIdList></Reference><Reference><Citation>Stekhoven, D. J. &amp; Bühlmann, P. Missforest-non-parametric missing value imputation for mixed-type data. Bioinformatics 28, 112–118 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22039212</ArticleId></ArticleIdList></Reference><Reference><Citation>Reyes-Silveyra, J. &amp; Mikler, A. R. Modeling immune response and its effect on infectious disease outbreak dynamics. Theor. Biol. Med. Model. 13, 1–21 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4779228</ArticleId><ArticleId IdType="pubmed">26944943</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO, N. C. Covid-19 therapeutic trial synopsis. R &amp; D Blue Print. https://www.who.int/publications/i/item/covid-19-therapeutic-trial-synopsis (2020).</Citation></Reference><Reference><Citation>Prozan, L. et al. Prognostic value of neutrophil-to-lymphocyte ratio in COVID-19 compared with influenza and respiratory syncytial virus infection. Sci. Rep. 11, 21519 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8563769</ArticleId><ArticleId IdType="pubmed">34728719</ArticleId></ArticleIdList></Reference><Reference><Citation>Henry, B. M. et al. Lactate dehydrogenase levels predict coronavirus disease 2019 (COVID-19) severity and mortality: A pooled analysis. Am. J. Emerg. Med. 38, 1722–1726 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7251362</ArticleId><ArticleId IdType="pubmed">32738466</ArticleId></ArticleIdList></Reference><Reference><Citation>Lundberg, S. M. &amp; Lee, S.-I. A unified approach to interpreting model predictions. Adv. Neural Inf. Process. Syst. 30, 4765–4774 (2017).</Citation></Reference><Reference><Citation>Yap, M. et al. Verifying explainability of a deep learning tissue classifier trained on RNA-seq data. Sci. Rep. 11, 2641 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7846764</ArticleId><ArticleId IdType="pubmed">33514769</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper, A., Doyle, O. &amp; Bourke, A. Supervised clustering for subgroup discovery: An application to COVID-19 symptomatology. In Joint European Conference on Machine Learning and Knowledge Discovery in Databases, 408–422 (Springer, 2021).</Citation></Reference><Reference><Citation>Clement, T., Nguyen, H. T. T., Kemmerzell, N., Abdelaal, M. &amp; Stjelja, D. Beyond explaining: Xai-based adaptive learning with shap clustering for energy consumption prediction. arXiv preprint arXiv:2402.04982 (2024).</Citation></Reference><Reference><Citation>Pedregosa, F. et al. Scikit-learn: Machine learning in python. J. Mach. Learn. Res. 12, 2825–2830 (2011).</Citation></Reference><Reference><Citation>Zimmerman, D. W. A note on preliminary tests of equality of variances. Br. J. Math. Stat. Psychol. 57, 173–181 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15171807</ArticleId></ArticleIdList></Reference><Reference><Citation>Szklarczyk, D. et al. The string database in 2021: Customizable protein-protein networks, and functional characterization of user-uploaded gene/measurement sets. Nucleic Acids Res. 49, D605–D612 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7779004</ArticleId><ArticleId IdType="pubmed">33237311</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanehisa, M. &amp; Goto, S. Kegg: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 28, 27–30 (2000).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC102409</ArticleId><ArticleId IdType="pubmed">10592173</ArticleId></ArticleIdList></Reference><Reference><Citation>Gudowska-Sawczuk, M. &amp; Mroczko, B. What is currently known about the role of CXCL10 in SARS-CoV-2 infection?. Int. J. Mol. Sci. 23, 3673 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8998241</ArticleId><ArticleId IdType="pubmed">35409036</ArticleId></ArticleIdList></Reference><Reference><Citation>Callahan, V. et al. The pro-inflammatory chemokines CXCL9, CXCL10 and CXCL11 are upregulated following SARS-COV-2 infection in an akt-dependent manner. Viruses 13, 1062 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8226769</ArticleId><ArticleId IdType="pubmed">34205098</ArticleId></ArticleIdList></Reference><Reference><Citation>Rochette, L., Zeller, M., Cottin, Y. &amp; Vergely, C. GDF15: An emerging modulator of immunity and a strategy in COVID-19 in association with iron metabolism. Trends Endocrinol. Metab. 32, 875–889 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8423996</ArticleId><ArticleId IdType="pubmed">34593305</ArticleId></ArticleIdList></Reference><Reference><Citation>Alserawan, L. et al. Growth differentiation factor 15 (GDF-15): A novel biomarker associated with poorer respiratory function in COVID-19. Diagnostics 11, 1998 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8625358</ArticleId><ArticleId IdType="pubmed">34829345</ArticleId></ArticleIdList></Reference><Reference><Citation>Brunetta, E. et al. Macrophage expression and prognostic significance of the long pentraxin PTX3 in COVID-19. Nat. Immunol. 22, 19–24 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33208929</ArticleId></ArticleIdList></Reference><Reference><Citation>Capra, A. P. et al. The prognostic value of pentraxin-3 in COVID-19 patients: A systematic review and meta-analysis of mortality incidence. Int. J. Mol. Sci. 24, 3537 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9958638</ArticleId><ArticleId IdType="pubmed">36834949</ArticleId></ArticleIdList></Reference><Reference><Citation>Shin, G.-C., Kang, H. S., Lee, A. R. &amp; Kim, K.-H. Hepatitis B virus-triggered autophagy targets TNFRSF10B/death receptor 5 for degradation to limit TNFSF10/TRAIL response. Autophagy 12, 2451–2466 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5173271</ArticleId><ArticleId IdType="pubmed">27740879</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen, Y., Qin, Y., Fu, Y., Gao, Z. &amp; Deng, Y. Integrated analysis of bulk RNA-seq and single-cell RNA-seq unravels the influences of SARS-CoV-2 infections to cancer patients. Int. J. Mol. Sci. 23, 15698 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9779348</ArticleId><ArticleId IdType="pubmed">36555339</ArticleId></ArticleIdList></Reference><Reference><Citation>Li, Q. et al. Immune response in COVID-19: What is next?. Cell Death Differ. 29, 1107–1122 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9110941</ArticleId><ArticleId IdType="pubmed">35581387</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu, B., Guo, H., Zhou, P. &amp; Shi, Z.-L. Characteristics of SARS-CoV-2 and COVID-19. Nat. Rev. Microbiol. 19, 141–154 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7537588</ArticleId><ArticleId IdType="pubmed">33024307</ArticleId></ArticleIdList></Reference><Reference><Citation>Merad, M. &amp; Martin, J. C. Pathological inflammation in patients with COVID-19: A key role for monocytes and macrophages. Nat. Rev. Immunol. 20, 355–362 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7201395</ArticleId><ArticleId IdType="pubmed">32376901</ArticleId></ArticleIdList></Reference><Reference><Citation>Coperchini, F. et al. The cytokine storm in COVID-19: Further advances in our understanding the role of specific chemokines involved. Cytokine Growth Factor Rev. 58, 82–91 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7837329</ArticleId><ArticleId IdType="pubmed">33573850</ArticleId></ArticleIdList></Reference><Reference><Citation>Li, S. et al. SARS-CoV-2 triggers inflammatory responses and cell death through caspase-8 activation. Signal Transduct. Target. Ther. 5, 235 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7545816</ArticleId><ArticleId IdType="pubmed">33037188</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu, M. et al. CXCL10/IP-10 in infectious diseases pathogenesis and potential therapeutic implications. Cytokine Growth Factor Rev. 22, 121–130 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3203691</ArticleId><ArticleId IdType="pubmed">21802343</ArticleId></ArticleIdList></Reference><Reference><Citation>Condamine, T., Ramachandran, I., Youn, J.-I. &amp; Gabrilovich, D. I. Regulation of tumor metastasis by myeloid-derived suppressor cells. Annu. Rev. Med. 66, 97–110 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4324727</ArticleId><ArticleId IdType="pubmed">25341012</ArticleId></ArticleIdList></Reference><Reference><Citation>Catanzaro, M. et al. Immune response in COVID-19: Addressing a pharmacological challenge by targeting pathways triggered by SARS-CoV-2. Signal Transduct. Target. Ther. 5, 84 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7255975</ArticleId><ArticleId IdType="pubmed">32467561</ArticleId></ArticleIdList></Reference><Reference><Citation>Costela-Ruiz, V. J., Illescas-Montes, R., Puerta-Puerta, J. M., Ruiz, C. &amp; Melguizo-Rodríguez, L. SARS-CoV-2 infection: The role of cytokines in COVID-19 disease. Cytokine Growth Factor Rev. 54, 62–75 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7265853</ArticleId><ArticleId IdType="pubmed">32513566</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaillon, S. et al. The long pentraxin PTX3 as a key component of humoral innate immunity and a candidate diagnostic for inflammatory diseases. Int. Arch. Allergy Immunol. 165, 165–178 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25531094</ArticleId></ArticleIdList></Reference><Reference><Citation>Wollert, K. C., Kempf, T. &amp; Wallentin, L. Growth differentiation factor 15 as a biomarker in cardiovascular disease. Clin. Chem. 63, 140–151 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28062617</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu, Z., Chen, X., Wang, C. &amp; Cheng, L. Novel genes/loci validate the small effect size of ERBB2 in patients with myasthenia gravis. Proc. Natl. Acad. Sci. 119, e2207273119 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9459313</ArticleId><ArticleId IdType="pubmed">35969801</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, H. et al. Molecular landscape of ERBB2 alterations in 14,956 solid tumors. Pathol. Oncol. Res. 28, 1610360 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9325965</ArticleId><ArticleId IdType="pubmed">35911441</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu, F. et al. Shared mechanisms and crosstalk of COVID-19 and osteoporosis via vitamin D. Sci. Rep. 12, 18147 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9614744</ArticleId><ArticleId IdType="pubmed">36307516</ArticleId></ArticleIdList></Reference><Reference><Citation>Lei, H. A single transcript for the prognosis of disease severity in COVID-19 patients. Sci. Rep. 11, 12174 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8190311</ArticleId><ArticleId IdType="pubmed">34108608</ArticleId></ArticleIdList></Reference><Reference><Citation>Lei, H. A two-gene marker for the two-tiered innate immune response in COVID-19 patients. PLoS ONE 18, e0280392 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9844909</ArticleId><ArticleId IdType="pubmed">36649304</ArticleId></ArticleIdList></Reference><Reference><Citation>Haljasmägi, L. et al. Longitudinal proteomic profiling reveals increased early inflammation and sustained apoptosis proteins in severe COVID-19. Sci. Rep. 10, 20533 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7689507</ArticleId><ArticleId IdType="pubmed">33239683</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>